Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S19, June 2016

Cord Blood-Derived Mesenchymal Stromal Cells for the Treatment of Graft-Versus Host Disease Following Hematological Stem Cell Transplantation

      Graft-versus-host disease (GvHD) is a severe complication in the setting of allogeneic hematopoietic stem cell transplantation (HSCT). Mesenchymal stromal cells (MSCs) have been extensively used as second-line treatment for acute GvHD. Cord blood (CB) MSCs display low immunogenicity which makes them suitable for an allogeneic use. Herein we reported the infusion of CB-MSCs to treat three patients with severe resistant aGvHD and two patients with overlap syndrome after HSCT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect